Jessica M Wilson, Catherine Lumley, Xianming Tan, Colette Shen, Andrew Coniglio, Mark Weissler, Wendell G Yarbrough, Trevor Hackman, Jeffrey Blumberg, Adam Zanation, Brian Thorp, Samip N Patel, Bhishamjit S Chera
{"title":"pT1-T2N0型口腔舌鳞癌患者的临床结局。","authors":"Jessica M Wilson, Catherine Lumley, Xianming Tan, Colette Shen, Andrew Coniglio, Mark Weissler, Wendell G Yarbrough, Trevor Hackman, Jeffrey Blumberg, Adam Zanation, Brian Thorp, Samip N Patel, Bhishamjit S Chera","doi":"10.1097/COC.0000000000000806","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to evaluate the clinical outcomes in a cohort of patients with early-stage oral tongue squamous cell carcinoma (OTSCC).</p><p><strong>Materials and methods: </strong>We conducted a retrospective analysis of patients with pT1-T2N0 (American Joint Committee on Cancer [AJCC] seventh edition) OTSCC treated from 2000 to 2018. Two-year actuarial rates of local regional control, cancer-specific survival, and overall survival were calculated for the entire cohort and patients with/without adjuvant radiation.</p><p><strong>Results: </strong>Ninety-six patients met the criteria with a median follow-up of 4 years; 14 had adjuvant radiation, while 82 had surgery alone. Two-year local regional control was 82.7% (75.4% to 90.8%) for the entire cohort, 84.9% (77.8% to 93.2%) for surgery only, and 70.7% (50.2% to 99.6%) for patients with adjuvant radiation. Two-year progression-free survival was 82.7% (75.3% to 90.8%). Of the 20 patients with recurrence, 11 (55%) were successfully salvaged.</p><p><strong>Conclusion: </strong>Local regional recurrence remains modest in early-stage OTSCC, but salvage is possible with high survival rates.</p><p><strong>Level of evidence: </strong>Level III-retrospective cohort study.</p>","PeriodicalId":501816,"journal":{"name":"American Journal of Clinical Oncology","volume":" ","pages":"200-205"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Clinical Outcomes of Patients With pT1-T2N0 Oral Tongue Squamous Cell Carcinoma.\",\"authors\":\"Jessica M Wilson, Catherine Lumley, Xianming Tan, Colette Shen, Andrew Coniglio, Mark Weissler, Wendell G Yarbrough, Trevor Hackman, Jeffrey Blumberg, Adam Zanation, Brian Thorp, Samip N Patel, Bhishamjit S Chera\",\"doi\":\"10.1097/COC.0000000000000806\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The objective of this study was to evaluate the clinical outcomes in a cohort of patients with early-stage oral tongue squamous cell carcinoma (OTSCC).</p><p><strong>Materials and methods: </strong>We conducted a retrospective analysis of patients with pT1-T2N0 (American Joint Committee on Cancer [AJCC] seventh edition) OTSCC treated from 2000 to 2018. Two-year actuarial rates of local regional control, cancer-specific survival, and overall survival were calculated for the entire cohort and patients with/without adjuvant radiation.</p><p><strong>Results: </strong>Ninety-six patients met the criteria with a median follow-up of 4 years; 14 had adjuvant radiation, while 82 had surgery alone. Two-year local regional control was 82.7% (75.4% to 90.8%) for the entire cohort, 84.9% (77.8% to 93.2%) for surgery only, and 70.7% (50.2% to 99.6%) for patients with adjuvant radiation. Two-year progression-free survival was 82.7% (75.3% to 90.8%). Of the 20 patients with recurrence, 11 (55%) were successfully salvaged.</p><p><strong>Conclusion: </strong>Local regional recurrence remains modest in early-stage OTSCC, but salvage is possible with high survival rates.</p><p><strong>Level of evidence: </strong>Level III-retrospective cohort study.</p>\",\"PeriodicalId\":501816,\"journal\":{\"name\":\"American Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"200-205\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/COC.0000000000000806\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000000806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Outcomes of Patients With pT1-T2N0 Oral Tongue Squamous Cell Carcinoma.
Objective: The objective of this study was to evaluate the clinical outcomes in a cohort of patients with early-stage oral tongue squamous cell carcinoma (OTSCC).
Materials and methods: We conducted a retrospective analysis of patients with pT1-T2N0 (American Joint Committee on Cancer [AJCC] seventh edition) OTSCC treated from 2000 to 2018. Two-year actuarial rates of local regional control, cancer-specific survival, and overall survival were calculated for the entire cohort and patients with/without adjuvant radiation.
Results: Ninety-six patients met the criteria with a median follow-up of 4 years; 14 had adjuvant radiation, while 82 had surgery alone. Two-year local regional control was 82.7% (75.4% to 90.8%) for the entire cohort, 84.9% (77.8% to 93.2%) for surgery only, and 70.7% (50.2% to 99.6%) for patients with adjuvant radiation. Two-year progression-free survival was 82.7% (75.3% to 90.8%). Of the 20 patients with recurrence, 11 (55%) were successfully salvaged.
Conclusion: Local regional recurrence remains modest in early-stage OTSCC, but salvage is possible with high survival rates.
Level of evidence: Level III-retrospective cohort study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
